Aucatzyl, a therapy to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia has received FDA approval. Aucatzyl joins Gilead’s Tecartus and Novartis’ Kymriah. Autolus has wrapped up all pre-launch activities and will now move to finish the final steps involved in onboarding treatment centers.
How to Create a Captivating Corporate Culture Video to Attract Top Talent, Clients
Creating a compelling video to showcase your business can be a powerful way to attract clients and job candidates. In today's digital age, video content is a critical component of your marketing strategy. By following a structured approach, you can craft a video that not only highlights your business but also engages and informs your audience effectively.
Building a Lasting Brand: Best Practices for Small Business Owners
In today's competitive marketplace, building a strong brand is crucial for the success of any small business. Your brand is not just a logo or a slogan—it's a complete expression of your business identity and a crucial tool for carving out a unique position in the market. Mastering certain foundational practices ensures your brand resonates with your audience, maintains authenticity, and drives business growth.
New data showing strong survival results
Johnson & Johnson and Legend Biotech’s Carvykti showed it could prevent disease progression in the earlier treatment of multiple myeloma, now results are showing that a single dose slashed the death risk by 45% compared with two traditional combination treatments in myeloma patients who had received at least one prior line of therapy, according to an update of the phase 3 CARTITUDE-4 trial.
CEO shares red flag she sees in employees
New Apple Watch feature approved by the FDA
FiercePharma's 50 of 2024
An effective way to answer a popular interview question
Gilead receives FDA Approval
I couldn’t get hired for a year—it changed my attitude toward work
FDA approval for Ascendis
The FDA has approved Ascendis’ Yorvipath, a hormone replacement therapy to treat hypoparathyroidism. Ascendis was ready to bring the drug to the market 15 months ago but was rejected due to a manufacturing problem. Then 3 months ago things were delayed when the FDA said they needed additional time to make its decision. Initial supplies should be available in the first quarter of 2025.
Roche to reintroduce eye implant to treat wet age-related macular degeneration
A 2022 recall stopped the launch of Roche's eye implant, Susvimo, due to manufacturing concerns. This is good news for patients with wet age-related macular degeneration (AMD) as Susvimo is a refillable eye implant that only requires two refills per year offering an alternative to standard-of-care eye injections to treat the disease.
A question to ‘always’ ask in a job interview
How Emotionally Intelligent People Use the Golden Question
First inhaled COPD treatment FDA approval in more than 20 years
Big Pharma's 10 highest-paid CEOs of 2023
AI mistakes job seekers are making
Advancements in cell & gene therapy manufacturing
2023 top 20 drugs by worldwide sales
Patent expirations and the rise of weight loss medications led to some surprises in the top 20 drugs by global sales. With more than 30 indications across various cancer types and stages, Merck’s Keytruda was top of the list last year. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total